Camrelizumab, a PD-1 inhibitor independently developed in China, was approved in June 2020 in combination with pemetrexed and carboplatin for the first-line treatment of unresectable locally advanced or metastatic nonsquamous NSCLC without EGFR and ALK alterations and was included in the first-line treatment recommendation of NSCLC and treatment guidelines of the Chinese Society of Clinical Oncology. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.